Cargando…
The Burden of Progressive-Fibrosing Interstitial Lung Diseases
Despite conventional treatment, a proportion of interstitial lung disease (ILD) patients develop a progressive phenotype known as “fibrosing ILD with a progressive phenotype” (PF-ILD), characterized by worsening respiratory symptoms, decline in lung function, and early mortality. This review describ...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843847/ https://www.ncbi.nlm.nih.gov/pubmed/35178411 http://dx.doi.org/10.3389/fmed.2022.799912 |
_version_ | 1784651353557041152 |
---|---|
author | Cottin, Vincent Teague, Rhiannon Nicholson, Lindsay Langham, Sue Baldwin, Mike |
author_facet | Cottin, Vincent Teague, Rhiannon Nicholson, Lindsay Langham, Sue Baldwin, Mike |
author_sort | Cottin, Vincent |
collection | PubMed |
description | Despite conventional treatment, a proportion of interstitial lung disease (ILD) patients develop a progressive phenotype known as “fibrosing ILD with a progressive phenotype” (PF-ILD), characterized by worsening respiratory symptoms, decline in lung function, and early mortality. This review describes the epidemiology, and the humanistic and economic burden of PF-ILDs other than idiopathic pulmonary fibrosis (non-IPF PF-ILD). A structured review of the literature was conducted, using predefined search strategies in Ovid MEDLINE and EMBASE, and supplemented with gray literature searches. The search identified 3,002 unique articles and an additional 3 sources were included from the gray literature; 21 publications were included. The estimated prevalence of non-IPF PF-ILD ranges from 6.9 to 70.3/100,000 persons and the estimated incidence from 2.1 to 32.6/100,000 person-years. Limited evidence demonstrates that PF-ILD has a significant impact on patients' quality of life, affecting their daily lives, psychological well-being, careers, and relationships. PF-ILD is also associated with significant economic burden, demonstrating higher healthcare resource use and direct costs compared with the non-progressive phenotype, and indirect costs, which include job losses. This review indicates that PF-ILD places a considerable humanistic burden on both patients and caregivers, and a substantial economic burden on healthcare systems, patients, and society. |
format | Online Article Text |
id | pubmed-8843847 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88438472022-02-16 The Burden of Progressive-Fibrosing Interstitial Lung Diseases Cottin, Vincent Teague, Rhiannon Nicholson, Lindsay Langham, Sue Baldwin, Mike Front Med (Lausanne) Medicine Despite conventional treatment, a proportion of interstitial lung disease (ILD) patients develop a progressive phenotype known as “fibrosing ILD with a progressive phenotype” (PF-ILD), characterized by worsening respiratory symptoms, decline in lung function, and early mortality. This review describes the epidemiology, and the humanistic and economic burden of PF-ILDs other than idiopathic pulmonary fibrosis (non-IPF PF-ILD). A structured review of the literature was conducted, using predefined search strategies in Ovid MEDLINE and EMBASE, and supplemented with gray literature searches. The search identified 3,002 unique articles and an additional 3 sources were included from the gray literature; 21 publications were included. The estimated prevalence of non-IPF PF-ILD ranges from 6.9 to 70.3/100,000 persons and the estimated incidence from 2.1 to 32.6/100,000 person-years. Limited evidence demonstrates that PF-ILD has a significant impact on patients' quality of life, affecting their daily lives, psychological well-being, careers, and relationships. PF-ILD is also associated with significant economic burden, demonstrating higher healthcare resource use and direct costs compared with the non-progressive phenotype, and indirect costs, which include job losses. This review indicates that PF-ILD places a considerable humanistic burden on both patients and caregivers, and a substantial economic burden on healthcare systems, patients, and society. Frontiers Media S.A. 2022-02-01 /pmc/articles/PMC8843847/ /pubmed/35178411 http://dx.doi.org/10.3389/fmed.2022.799912 Text en Copyright © 2022 Cottin, Teague, Nicholson, Langham and Baldwin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Cottin, Vincent Teague, Rhiannon Nicholson, Lindsay Langham, Sue Baldwin, Mike The Burden of Progressive-Fibrosing Interstitial Lung Diseases |
title | The Burden of Progressive-Fibrosing Interstitial Lung Diseases |
title_full | The Burden of Progressive-Fibrosing Interstitial Lung Diseases |
title_fullStr | The Burden of Progressive-Fibrosing Interstitial Lung Diseases |
title_full_unstemmed | The Burden of Progressive-Fibrosing Interstitial Lung Diseases |
title_short | The Burden of Progressive-Fibrosing Interstitial Lung Diseases |
title_sort | burden of progressive-fibrosing interstitial lung diseases |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843847/ https://www.ncbi.nlm.nih.gov/pubmed/35178411 http://dx.doi.org/10.3389/fmed.2022.799912 |
work_keys_str_mv | AT cottinvincent theburdenofprogressivefibrosinginterstitiallungdiseases AT teaguerhiannon theburdenofprogressivefibrosinginterstitiallungdiseases AT nicholsonlindsay theburdenofprogressivefibrosinginterstitiallungdiseases AT langhamsue theburdenofprogressivefibrosinginterstitiallungdiseases AT baldwinmike theburdenofprogressivefibrosinginterstitiallungdiseases AT cottinvincent burdenofprogressivefibrosinginterstitiallungdiseases AT teaguerhiannon burdenofprogressivefibrosinginterstitiallungdiseases AT nicholsonlindsay burdenofprogressivefibrosinginterstitiallungdiseases AT langhamsue burdenofprogressivefibrosinginterstitiallungdiseases AT baldwinmike burdenofprogressivefibrosinginterstitiallungdiseases |